Jakafi® (ruxolitinib) may help control hematocrit (percentage of red blood cell volume) and reduce spleen size in adults with polycythemia vera (PV) who did not benefit from treatment with hydroxyurea (HU) or could not tolerate it.
Did you know that the spleen may become enlarged in people with PV?
Learn how you can help identify the signs and symptoms of spleen enlargement.
Jakafi was compared against other standard therapies in a clinical trial of adults with PV who had already taken a medicine called HU and it did not work well enough or they could not tolerate it. Treatment was said to be effective if Jakafi kept a patient’s hematocrit level under control, while at the same time reducing spleen size by at least 35%.
The combination of these two measurements (hematocrit control and spleen size reduction) made up the primary endpoint, or the main goal, of the study.
After approximately 8 months of therapy:
Primary endpoint
23% (25 of 110) of patients in the group that received Jakafi kept their hematocrit under control and had a reduction in spleen size of at least 35% compared with <1% (1 of 112) of patients in the group that received other treatments
Hematocrit portion of the primary endpoint
60% (66 of 110) of patients in the Jakafi group kept their hematocrit under control without phlebotomy compared with 19% (21 of 112) of patients in the group that received other therapies
Spleen size portion of the primary endpoint
40% (44 of 110) of patients in the group receiving Jakafi had at least a 35% reduction in their spleen size compared with <1% (1 of 112) of patients who received other therapies
Take an active role in identifying spleen enlargement in PV
Learn how you can partner with your Healthcare Professional to help identify the signs and symptoms of spleen enlargement in PV.
Professional Perspective:
What Effects Has Jakafi Shown in Clinical Trials?
Learn how targeted therapy with Jakafi affected patients’ hematocrit control, blood counts and spleen size after 8 months of treatment, when compared against other standard therapies.
Because PV can affect not only red blood cells, but also white blood cells and platelets, researchers looked at all 3 blood counts (red blood cells, white blood cells, and platelets) and whether Jakafi helped control them. This was a secondary goal (or secondary endpoint) of the clinical trial.
Results of the clinical trial demonstrated that more patients receiving Jakafi achieved the combined goal of hematocrit (HCT) control plus white blood cell (WBC) count and platelet count within goal ranges compared with other standard therapies. After approximately 8 months of therapy:
Patient Perspectives: Cindy’s Story
An unusually high hematocrit level led to Cindy’s diagnosis of PV. Learn how she moved her treatment journey forward with Jakafi.
Additional analyses of the key clinical trial for Jakafi were conducted at 20 months to look at the potential for PV patients to maintain the primary response of HCT control plus spleen size reduction of at least 35%.
Of the 25 patients who achieved the primary goal of hematocrit control plus spleen size reduction of at least 35% at 8 months:
76% (19 of 25) maintained their response at approximately 20 months
Of the 66 patients who achieved hematocrit control at 8 months:
77% (51 of 66) maintained hematocrit control at approximately 20 months
Of the 26 patients who achieved the secondary endpoint of HCT control and had WBC and platelet counts within goal range at 8 months:
58% (15 of 26) maintained this response at approximately 20 months
Every person is unique. How your PV progresses and how you will respond to Jakafi depends on your individual circumstances. Talk to your Healthcare Professional to learn more about how patients responded to Jakafi in the key clinical trial and ask about the potential long-term effects of Jakafi treatment.
Jakafi can cause serious side effects, including:
Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.
Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.
Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.
Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.
Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech
Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing
Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.
The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.
These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.
Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.
Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.
Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.
Learn how you can partner with your Healthcare Professional to help identify and monitor the signs and symptoms of spleen enlargement in PV.
Learn MoreJAKAFI or JAKAFI XR (ruxolitinib) is a prescription medication used to treat adults with certain types of myelofibrosis (MF).
It is not known if JAKAFI or JAKAFI XR is safe or effective in children for treatment of myelofibrosis.
JAKAFI or JAKAFI XR is a prescription medication used to treat adults with polycythemia vera (PV) who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.
It is not known if JAKAFI or JAKAFI XR is safe or effective in children for treatment of polycythemia vera.
JAKAFI or JAKAFI XR is a prescription medication used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.
JAKAFI or JAKAFI XR is a prescription medication used to treat adults and children 12 years of age and older with chronic graft-versus-host disease (GVHD) who have taken one or two types of treatments and they did not work well enough.
JAKAFI or JAKAFI XR can cause serious side effects, including:
Low blood counts: JAKAFI or JAKAFI XR may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking JAKAFI or JAKAFI XR and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start and regularly during your treatment. Your healthcare provider may change your dose or stop your treatment based on the results of your blood tests.
Tell your healthcare provider right away if you develop or have worsening symptoms such as
Infection: You may be at risk for developing a serious infection during treatment with JAKAFI or JAKAFI XR. Tell your healthcare provider if you develop any of the following symptoms of infection:
Worsening of symptoms after interrupting or stopping treatment. Signs and symptoms of myelofibrosis may worsen after you stop treatment.
Do not interrupt or stop treatment without talking to your healthcare provider. Tell your healthcare provider right away if you have any of the following after stopping treatment:
Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with JAKAFI or JAKAFI XR. Your healthcare provider will regularly check your skin during your treatment. Tell your healthcare provider if you develop any new or changing skin lesions during treatment.
Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with JAKAFI or JAKAFI XR. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking JAKAFI or JAKAFI XR and as needed.
Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis:
Get emergency help right away if you get any symptoms of a heart attack or stroke during treatment with JAKAFI or JAKAFI XR, including:
Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening.
Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with JAKAFI or JAKAFI XR, including:
Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.
The most common side effects of JAKAFI or JAKAFI XR include:
These are not all the possible side effects. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.
Before taking JAKAFI or JAKAFI XR, tell your healthcare provider about:
Women should not take JAKAFI or JAKAFI XR while pregnant or planning to become pregnant. Do not breastfeed during treatment with JAKAFI or JAKAFI XR and for 2 weeks after the final dose.
How should I take JAKAFI or JAKAFI XR?
Please see the Full Prescribing Information, including Patient Information, which includes a more complete discussion of the risks associated with JAKAFI or JAKAFI XR.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
You may also report side effects to Incyte Medical Information at 1-855-463-3463.
Thank you for visiting.
You are now leaving the Jakafi.com website. This link will take you to a site that is not owned or maintained by Incyte Corporation, and Incyte is not responsible for the information contained on third-party sites.
